Enliven Therapeutics, Inc. (ELVN) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $98.90M | -20.3% |
| 2024 | $124.12M | +23.9% |
| 2023 | $100.14M | +32.6% |
| 2022 | $75.54M | +56.4% |
| 2021 | $48.31M | +1.3% |
| 2020 | $47.70M | +866.3% |
| 2019 | $4.94M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $98.90M | -20.3% |
| 2024 | $124.12M | +23.9% |
| 2023 | $100.14M | +32.6% |
| 2022 | $75.54M | +56.4% |
| 2021 | $48.31M | +1.3% |
| 2020 | $47.70M | +866.3% |
| 2019 | $4.94M | — |